https://www.immunogen.com/wp-content/uploads/2023/06/EHA2023-IMGN632-801-BPDCN_abs-S139-VF.pdf

 

*CORRECTION*
1L Efficacy:

 

Elz:  90% ORR, 72% CR/CRc (https://www.elzonris.com/hcp/treatment-naive)

PVEK: 80% ORR, 73% CR/CRc

 

Note that for the pivotal cohort on Elzonris which had less follow up time and is likely more similar to early PVEK data we had:

 

Elz: 77% ORR, 54% CR/CRc

PVEK: 80% ORR, 73% CR/CRc 

 

R/R Efficacy: 

 

Elz: 67% ORR, 13% CR/CRc (https://www.elzonris.com/hcp/previously-treated)

PVEK:  33% ORR, 20% CR/CRc

 

Safety:

 

Elz:
11% discontinuation
Capillary Leak Syndrome (leads to Grade 5 events) 55% (9% GR3+)

Liver enzyme elevation 40% GR3+

PVEK:
3% discontinuation

Capillary Leak Syndrome 0%

Liver enzyme elevation 3% GR3+ 

 

Safety should read out well to AML potentially, but PVEK is likely to be a bigger deal in a buyout than Mirv. due to addressable AML market despite its under-the-radar lack of coverage by analysts.